Alicia is a PhD candidate in the Harvard-MIT Health Sciences and Technology program. Her research focuses on using mass spectrometry based proteomics to characterize altered kinase signaling at the tumor-immune interface. Using a systems biology approach, she hopes to better understand how treatments can better target immune cells to eradicate cancer cells. Alicia grew up in Dallas, Texas and earned her Bachelor of Science in Chemical Engineering from Stanford University. In her free time, Alicia enjoys traveling and trying new restaurants.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

Improvements in xenotransplantation. I look forward to improved engineering and clinical expertise to allow us to transplant either artificial organs or organs from other animals into patients. I was incredibly excited by the news of the recent pig kidney transplant and look forward to a future where families can be assured their loved one can receive the organ transplant they need.

‍

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

Factfulness by Hans Rosling - this book offers a refreshing perspective on the progress the world has made, particularly in health in developing nations.

‍

FROM YOUR PERSPECTIVE, WHAT RECENT INNOVATION HAS HAD THE GREATEST IMPACT IN TECH/HEALTH?

ChatGPT - This might be the most transformative innovation from the past 5 years. From a health perspective, it has had a tremendous impact on empowering patients and their families to better understand their conditions and medical information.

Ben is a third-year ophthalmology resident at Bascom Palmer Eye Institute. He previously studied Molecular and Cellular Biology at Yale University and was a full-ride Woodruff Fellow at Emory University School of Medicine. His research has spanned neuro-regeneration, genetics, retina, and neuro-ophthalmology. He is interested in the intersection of technology, business, and ophthalmology. His passions outside of work include hiking, baking, and spending time with his dog, Ralph. 

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

A cure for blindness. More specifically, the ability to regenerate and direct retinal ganglion cells and optic nerve axons to afford functional visual recovery. That would be incredible. 

‍

GREATEST ACCOMPLISHMENT

Learning an entirely new sport (water polo) as a freshman in college, and then ultimately becoming the starting goalie and team captain by my senior year. 

‍

GREATEST IMPACT IN TECH/HEALTH

In-vivo gene therapy. Opens up new spaces within medicine, tech, and therapeutics that were otherwise inconceivable.

Ben is an MD/MBA candidate at Stanford University. Much of his research is in dermatology, which he believes is a field that uniquely blends the psychological and physiological elements of human wellness. He has largely focused on identifying and categorizing allergens in over-the-counter skincare products, the intersection of dermatology and rheumatology, and the skin toxicities of cancer immunotherapies. Ben has also worked in performance improvement at Lucile Packard Children's Hospital, where he spearheaded operational initiatives to optimize discharge processes. 

Outside of dermatology, Ben is committed to LGBTQ+ health, and has led and served on multiple LGTBQ+ committees at the Stanford of Medicine. He also conducts research with the PRIDE Study, the world's first large-scale, long-term national health study of LGBTQ+ individuals.

Ben received his BA in religious studies and his BS in biology from Stanford University. In his free time, he derives immense fulfillment from storytelling and serves as one of the GSB's TALK Coaches. He also enjoys playing and watching tennis, and considers meeting Venus Williams one of his happiest moments. Finally, he is passionate about 90s pop music, and you'll often find him with one AirPod in, listening to Mariah Carey.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Personalized diagnostics and therapeutics for Alzheimer’s Disease that prevent and reverse cognitive decline. I believe the field is at the cusp of an inflection point and am optimistic that advances in multi-omics sequencing, cell therapies, and AI will yield a new generation of therapeutics that go beyond targeting hallmark proteinopathies.

‍

WHAT EXCITES YOU ABOUT ARTIS

I’m excited to see TechBio companies building ventures around cutting-edge science and technologies I have never imagined. It’s incredibly inspiring to see ingenuity translated into ventures that can improve human health.

‍

GREATEST IMPACT IN TECH/HEALTH

By combining generative AI and high-throughput single-cell -omics, researchers can now model cellular dynamics through space and time in disease, revealing new therapeutic targets. I expect this will yield a comprehensive "digital cell" atlas of health and disease for ubiquitous use, akin to the human genome. Advanced sequencing gives us letters; AI gives us grammar.

Cameron is completing a PhD in the Howarth Lab at the University of Cambridge, UK. His research focuses on engineering highly stable antibody mimetic proteins for action in the gastrointestinal tract. Disease targets of particular interest include the inflammatory pathways involved in IBD, the microbiome, food intolerances and microbial infection. Cameron completed a masters degree in the Biggin Group (University of Oxford) using protein MD simulation and high-throughput fragment-based drug design to inhibit novel cancer targets. He now uses this computational experience to complement protein display technologies for antibody design. Cameron is also involved in growing the new chapter of Nucleate in the UK.

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

I’d love to see some causative rather than correlative data for the influence of the microbiome of human health and disease. I have personal reasons to want the development of a cure for Parkinson’s disease. I think the extension of healthy lifespan by targeting aging itself is an interesting all-in-one concept for healthcare. Perhaps in my lifetime we will see the discovery of the elusive partial epigenetic reprogramming factors that can rejuvenate specialized cell types.

WHAT EXCITES YOU ABOUT ARTIS

For starters, it is always exciting for a Brit to venture over to The Valley! Joking aside, I am impressed by the clarity of vision at ARTIS. Using the consistency of tech innovation to give life science ideas the boost they often require is really exciting - and ARTIS has the team to do it. I think it’s all about people - the partners, the network of advisors, the amazing founders and the other fellows - that is the secret sauce. I’m excited to learn from these remarkable people and contribute to the ARTIS family.

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD GREATEST IMPACT ON TECH/HEALTH

Having one foot in computational protein design, it would be remiss not to mention AlphaFold. While I think we’ll be waiting a fair while before ML is spitting out de novo, high affinity biologics without requiring some additional wet-lab development, AlphaFold has really opened up the game.

Caroline completed her BSc in Biological Sciences at UC Santa Barbara, where she discovered her passion for biomedical research. After graduating, she worked at Surrozen, where she contributed to the preclinical development of regenerative medicines for severe liver diseases. She then went on to pursue a PhD in Pharmacology at Weill Cornell Graduate School of Medical Sciences. She completed her thesis work in Scott Lowe’s laboratory at Memorial Sloan Kettering Cancer Center, where the overarching goal of her research was to leverage senescence biology to increase the immune ‘visibility’ of immunosuppressive cancers like pancreatic cancer. Caroline is passionate about translating biomedical discoveries into novel therapies.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

I hope to see technologies that enable accurate, early detection of cancer become accessible to all patients. Early detection significantly increases the chances of successful treatment, and far too many cancers are diagnosed at advanced stages. A number of companies are pursuing early pan-cancer diagnostic technologies, which will hopefully evolve into the standard of care.

‍

WHAT EXCITES YOU MOST ABOUT TECHBIO?

To me, the most exciting aspect of TechBio is its rapid transformation. With ‘omics’ data becoming increasingly accessible and machine learning technologies advancing swiftly, the way we discover and develop new therapies is set to accelerate dramatically. I am eager to contribute to this innovative field and help create a future where personalized medicine is the norm, treatments are tailored to individual genetic profiles, and where previously incurable diseases can be effectively managed or cured.

‍

FROM YOUR PERSPECTIVE, WHAT RECENT INNOVATION HAS HAD THE GREATEST IMPACT IN TECH/HEALTH?

From my perspective, the recent innovation that has had the greatest impact in tech/health is mRNA technology. The rapid development of COVID-19 vaccines using mRNA platforms saved countless lives and garnered global attention, but mRNA technology holds immense potential beyond infectious diseases.

Early clinical data has demonstrated that personalized mRNA vaccines can be successfully used to treat pancreatic cancer, one of the most challenging cancers to manage. mRNA technology is also poised to eliminate the need for labor-intensive and costly ex vivo cell engineering and adoptive cell therapy, making treatments more accessible and scalable. I believe mRNA is positioned to become a key treatment modality for a variety of diseases.

I am a 4th year Cancer Biology PhD candidate in the Bassik and Greenleaf labs at Stanford. I’m interested in the intersection between technology development, epigenetics, and tumor immunology. At Stanford, I study how macrophage state and function changes upon cancer cell phagocytosis during mAb treatment. This work can help us understand the regulators that drive dysfunctional macrophage states in cancer.

In my undergrad at Columbia University, I studied environmental science and biology—I’ve always been interested in how to transform scientific advancements into tangible action, whether through climate policy or therapeutics in biotech. I’ve worked on a wide range of problems from measuring background gamma radiation following nuclear weapons testing to developing better in vitro models to study tumor invasion. Following my undergrad, I worked in the Regev and Lander labs at the Broad Institute of Harvard and MIT to build a screening platform for human transcription factor domains to develop better tools for genetic engineering. Outside of research, I love live music, doing ceramics, and playing tennis.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

Increased accessibility of early cancer diagnostics and personalized cancer treatment.

‍

WHAT EXCITES YOU MOST ABOUT TECHBIO?

I am most excited by TechBio's potential to increase the pace of scientific progress. TechBio will enable the development of tools that leverage the availability of multiomics data to accelerate drug discovery, design de novo proteins for genome engineering, and bring therapeutics to the clinic faster.

‍

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

Trick Mirror by Jia Tolentino. A thought-provoking collection of essays on how our self-perception is shaped by the rise of internet culture.

Cheng Kai Lim is a PhD-MBA student at the National University of Singapore, where he works on synthetic biology and DNA data storage. He is interested in developing tools that can enable everyone to engineer biology more effectively, thereby accelerating the process of bringing therapies to market. He is also keen on new models for doing science and how it can be more equitable. He was previously with iGEM as the Global Chair of their Entrepreneurship Programme (EPIC), and has worked in multiple biotech startups, helping them drive their business development efforts. Cheng Kai was a Leader of Tomorrow for the 2020 iteration of the GapSummit, a conference dedicated to selecting top potential biotech leaders, and was also a highly commended awardee for the Global Undergraduate Thesis awards.

In his free time, Cheng Kai enjoys playing the piano, bouldering and reading all sorts of content - online or offline.

‍

GREATEST ACCOMPLISHMENT

Starting and running a completely virtual incubator programme for aspiring Synthetic Biology entrepreneurs for the past two years of the pandemic, and seeing some of the companies grow and thrive has been the most fulfilling thing of my life (so far!).

‍

WHAT EXCITES YOU ABOUT ARTIS

To me, ARTIS is a pioneer in the TechBio space, which is something that I've always been interested in, but never conceptually developed until now. I believe that working with ARTIS will allow me to immerse myself in this space, and hopefully inspire me to start a TechBio company of my own!

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD GREATEST IMPACT ON TECH/HEALTH

The change in mindset for scientists to think about potential commercialization of their work. The shift in career paths from academia to entrepreneurship, driven by the many innovations in bio-startup models, will likely be the genesis of the next TechBio game changers.

Coco is studying medicine (MD) at the University of Newcastle. She has previously completed a Bachelor of Science, majoring in immunology, from the University of Sydney, Science Honours from the University of New South Wales and has conducted additional research at The Garvan Institute of Medical Research into Parkinson’s Disease. Her honours research surrounded the role of mitochondrial dysfunction in neurodegenerative disease and focused on utilising CRISPR to evaluate potential disease modifying genes.Coco is particularly interested in Internal medicine, Rheumatology, Oncology and Paediatrics and completed a placement at the New York Centre for Children in early 2020. Outside of Medicine she participates in the AIME Mentorship Program, supporting Australian Indigenous High school students and volunteers at the BOP Homeless Shelter.When she’s not studying or volunteering you can find her, running, hiking, swimming, practicing yoga or walking her dog.

‍

GREATEST ACCOMPLISHMENT

• Rowing on the Australian National team
• My resilience in pursuing medicine and maintaining a positive mindset when faced with ongoing symptoms of my autoimmune disease

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

• A more personalised approach to medicine
• Shift in oncology towards patient specific cell therapy, utilising genetically engineered immune cells specifically targeted to patient tumour cells
• Advances in preventative medicine through the use of genomic sequencing as a screening tool

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

'The Boy Who Was Raised as a Dog' by psychiatrist Dr. Bruce D. Perry. It opened my eyes to the world of public health and how prevention and treatment of trauma in children and adolescents can have dramatic impacts on systemic health as an adult.

Danilo is a 3rd year Genetics PhD student at Stanford University in Dr. Nicolas Altemose's lab working on integrating machine learning with single-molecule sequencing. He completed his B.S in Biochemistry at the University of Washington, where he worked with Dr. Kathleen Millen on deciphering the underlying genetic mechanisms of cerebellar disorders. He then completed a M.S. in Bioengineering and Bioinformatics with Dr. Chris Vollmers at UCSC, working on single-molecule transcriptomics. Before coming to Stanford, he was a computational biologist in Dr. Andrew Stergachis's lab at the University of Washington, where he worked on epigenetically charting previously unmappable portions of the genome.When he's not in the lab, you can find Danilo skiing or backpacking in the Sierras, or exploring San Francisco.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

I would love to see the integration of omics assays with machine learning to enable more powerful personalized medicine approaches as well as enabling earlier prognosis of diseases such as cancer.

‍

WHAT EXCITES YOU MOST ABOUT TECHBIO?

TechBio is so exciting to me because the development of powerful new platforms opens up new doors in biology. Scientific inquiries are often limited by the tools available and TechBio development pushes the envelope on what is possible.

‍

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

A Brief History of Time by Stephen Hawking really inspired me to think about how to communicate science in a digestable way, and that no question is too big to answer.

‍

FROM YOUR PERSPECTIVE, WHAT RECENT INNOVATION HAS HAD THE GREATEST IMPACT IN TECH/HEALTH?

Nanopore sequencing and the rise of automated T2T assemblies.

‍

WHAT IS YOUR GREATEST ACCOMPLISHMENT?

I've never liked running, so running my 1st half-marathon last year has been one of my biggest accomplishments!

David is a Bioengineering PhD student at the University of Pennsylvania in Dr. Carl June's Lab working on T cell engineering to enhance function in solid tumor settings. Previously, he completed undergraduate degrees in Bioengineering and Electrical Engineering and Computer Sciences at UC Berkeley, where he worked on magnetic particle imaging and point-of-care diagnostics research, which he took through the NSF I-Corp program and UC LAUNCH accelerator as a startup called Clean Slate.

A San Francisco native, David enjoys outdoor adventures and trying new bakeries, and appreciates a good public transportation system. He currently focuses his free time on keeping up with new science and tech, rock climbing, and improving his pottery practice.

‍

GREATEST ACCOMPLISHMENT

Becoming the first person in my family to go to graduate school working toward becoming the first to obtain a PhD.

‍

MOST INFLUENTIAL CONTENT READ/LISTENED TO IN PAST YEAR

"Range" by David Epstein, which discusses how there is value in spending more time exploring as a generalist as opposed to becoming a specialist earlier. Broadened thinking and cross-domain experiences have characterized some of the most successful people in their trades, and become more advantageous in a society where some specializations can be delegated to machine intelligence.

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD GREATEST IMPACT ON TECH/HEALTH

Computation-augmented design of therapeutic molecules both chemical and biomolecular. Advances in computational methods combined with increases in the amount and generation of high-quality data has uniquely enabled the development and testing of molecules unknown to our understanding of the natural world.

Dillan is a fourth year MD Candidate at the Icahn School of Medicine at Mount Sinai and Research Fellow at the Children’s Hospital of Philadelphia in the Division of Plastic & Reconstructive Surgery.  His current research includes translational innovation, applications of machine learning to clinical datasets, and global surgery.

Dillan graduated from Johns Hopkins with a BA in Medicine, Science, & the Humanities and Anthropology as a Hodson Scholar. During undergraduate he pursued a year studying Biochemistry at Oxford and a semester in Sydney at the Garvan Institute.  Previous research at Johns Hopkins Medicine on neuronal synaptic plasticity and sensory impairment was supported by the James West Fellowship, Robert Young Grant, and Provost Undergraduate Research Award.  He has authored over forty peer-reviewed publications and 100 abstracts.

In the community he enjoys serving as Co-Chair of the Young Leadership Board for Smile Train, as Co-Chair of the Curriculum Committee for the Gay and Lesbian Medical Association, and on the Advisory Board of the Hispanic Scholarship Fund.

‍

MOST INFLUENTIAL CONTENT READ/LISTENED TO IN PAST YEAR

"Grit" by Angela Duckworth

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Advancement of CRISPR-based therapies for currently incurable conditions including HIV

‍

GREATEST ACCOMPLISHMENT

Attending undergraduate and medical school covered by scholarships and grants

Donna Taraborelli is a Doctor of Public Health candidate at Harvard. As part of her doctoral research, she worked with a startup founded by a sleep scientist who developed a platform technology to shift human circadian rhythms to optimize sleep. Donna is the co-Managing Director of Nucleate Genesis, a student-led venture creation education program for life science trainees, and is on the leadership team of the Public Health Innovation x Technology Student Forum.  She was previously a fellow with Yard Ventures and Harvard’s Office of Technology Development. Donna and her team were also part of Harvard i-Lab’s Venture Incubation Program and semi-finalists in the President’s Innovation Challenge.

Prior to Harvard, Donna worked in drug development across big and small pharmaceutical companies. Most recently, her work supported Clearside Biomedical’s IPO in 2016.  She also co-led the company’s first new drug application for XIPERETM, approved in 2021 for the treatment of noninfectious uveitis, and spearheaded the company’s ocular gene therapy delivery program.

‍

GREATEST ACCOMPLISHMENT

Being accepted into Harvard’s Doctor of Public Health program was a dream come true!

‍

MOST INFLUENTIAL CONTENT READ/LISTENED TO IN PAST YEAR

"Unhealthcare: A Manifesto for Health Assurance" by Hemant Taneja & Stephen Klasko

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD GREATEST IMPACT ON TECH/HEALTH

Next generation genomic sequencing is important for the identification and surveillance of new pathogens to prevent and control outbreaks such as COVID-19. The data generated gives us the ability to estimate the prevalence of variants at a population level and optimize development of targeted treatments and vaccines.

Emily is a 6^th year MD/PhD candidate at Duke University School of Medicine, where she studies under the mentorship of Dr. Peter Fecci in the Duke Brain Tumor Immunotherapy Program. Emily’s research focuses on characterizing MHC-I-independent CD8 T cell cytotoxicity as well as developing novel cancer therapies to combat tumor heterogeneity and antigen escape.

She previously completed a Master of Health Science in Duke University School of Medicine’s Clinical Research Training Program and an undergraduate degree in neuroscience from Northwestern University.

Outside of work, Emily enjoys spending time with her family and friends, baking & cake decorating, mountain biking, and glass blowing.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

‍I hope that personalized treatment for cancer becomes commonplace. Tumors are incredibly heterogeneous, both between patients, and on a cellular level within an individual tumor. Our treatment strategies must be equally diverse and tailored.

‍

GREATEST ACCOMPLISHMENT

The manuscript of my PhD thesis work, which revolves around the groundbreaking discovery that CD8+ T cells can execute cytotoxicity against tumor cells in an antigen-independent and MHC-independent manner. This challenges the conventional understanding of how CD8 T cells kill tumors and suggests that individuals with MHC-I mutations can still benefit from CD8 T cell-dependent immunotherapies.

‍

GREATEST IMPACT IN TECH/HEALTH

One of the notable advancements in oncology in recent years is the success of antibody drug conjugates (ADCs), especially in treating metastatic HER2+ breast cancer. ADCs demonstrate superior responses compared to monoclonal antibodies alone, even in cases of low target expression (such as HER2 low).

Emily is a Biomedical Engineering PhD candidate at Johns Hopkins University, where she also completed her bachelor’s degrees in Biomedical Engineering and Applied Math & Statistics. Her research centers on developing computational tools to aid in unraveling regulatory network structures within the cell and controlling cell identity transitions, with a particular focus in stem cell and developmental biology. Prior to graduate school, she worked in a synthetic biology lab where she studied calcium signaling and mechanosensation in primary cilia.

Outside of the lab, Emily dedicates time toward mentoring and teaching. She’s passionate about increasing diversity, inclusion, and innovation across STEM by making science approachable and by empowering young adults to pursue STEM fields. Beyond undergraduate courses, her teaching pursuits have also included developing stem cell biology summer immersion programs for high school students.

In her free time, Emily loves streaming drama series and indulging in ice cream and coffee.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Any advances in regenerative medicine or biotherapeutics that would help assuage the organ transplant crisis

‍

GREATEST ACCOMPLISHMENT

As a kid, overcoming a fear of water, learning how to swim, and eventually joining the swim team

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD THE GREATEST IMPACT ON TECH/HEALTH

Single-cell omics and analysis

Eriona Hysolli is a Postdoctoral Researcher in George Church's lab at Harvard Medical School, with a background in stem cell biology, synthetic bio and genetics. While at Harvard, Eriona has worked both on the GP Write Consortium and Woolly Mammoth Revival.

Previously, she was a graduate student at Yale University studying reprogramming of human fibroblasts to iPSCs.

Outside of work, Eriona is an avid table tennis player and hiker and enjoys writing about science in the form of press releases, and long-form stories.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

In the near future, replacing cells/organs using stem cell technologies to increase quality of life and life expectancy.

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

Studies from Roland Griffiths, PhD, on using psychedelics to treat disorders of the mind.

‍

WHAT EXCITES YOU ABOUT ARTIS

Partaking in a process that makes change happen, instead of hoping it happens.

Fatima is a Postdoctoral Fellow at Stanford University School of Medicine. Her research in the Sonnenburg Lab focuses on the rational design of the gut microbiota with the goal of controlling the persistence and abundance of bacterial strains.

She was born in Bangladesh and grew up in Saudi Arabia before packing her two suitcases to go to graduate school in the US. Fatima received her PhD in Chemical Engineering from Iowa State University, where she was an NSF Trinect Fellow and a Brown Graduate Fellow.

In her graduate work, she harnessed the programmability of microbes to help elucidate the staggering complexity of glycans and expand the glycobiology toolbox.

Outside of work, Fatima enjoys hiking, perfecting her recipes and she loves boba tea.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Engineered bacterial therapeutics approved for use in humans that deliver a clinically meaningful impact on disease in patients.

‍

GREATEST IMPACT IN TECH/HEALTH

I am currently reading 'The Code Breaker', an incredible biography on Jennifer Doudna by Walter Isaacson. From detailed moments in the race to understand CRISPR, to ethics in gene editing in humans, the book is enlightening and emphasizes how important curiosity is to advancing science.

‍

WHAT EXCITES YOU ABOUT ARTIS

I am most excited about this opportunity because it merges my passion for biology, innovation and business to solve our world's most pressing issues. Scouring the world for the brightest entrepreneurs with the boldest ideas in TechBio and helping them live out their potential excites me.

"Felix is a postdoctoral fellow in Professor Moore's group at UMass Chan Medical School. His research applies machine learning methods to understand DNA regulation.Felix completed his undergraduate studies in mathematics in France before earning an MSc in computer science from Telecom Paris. He then obtained his PhD in computational biology through a joint position between Mines Paris, Institut Curie and Google DeepMind.His doctoral research focused on evaluating AI methods for analyzing single-cell multiomics data in Triple Negative Breast Cancer. Following his PhD, Felix led the target discovery team at an immuno-oncology biotech startup before returning to academia.Felix's research interests lie at the intersection of wet and dry lab work. He aims to design experiments and datasets that are conducive to machine learning analysis, bridging the gap between experimental biology and computational methods.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

The healthcare advancement I hope to witness in my lifetime is a comprehensive molecular understanding of neurological and psychiatric conditions. Our current limited knowledge in this area significantly hinders our ability to diagnose, classify, and effectively treat patients. This gap in understanding leads to a substantial burden on both patients and their families.A deeper molecular insight into these conditions would likely revolutionize our approach to mental health and neurological disorders. It could potentially lead to more precise diagnostics, personalized treatment strategies, and ultimately, better outcomes for those affected. This advancement would not only improve individual patient care but could also alleviate the broader societal and economic impacts of these conditions.

‍

WHAT EXCITES YOU MOST ABOUT TECHBIO?

What excites me most about techbio is that it represents the natural evolution of biology as a field. Techbio, and computational biology as a whole, are attempting to understand the fundamental rules of biology by applying systematic reasoning to it.In my view, techbio is poised to be the Newtonian revolution of biology. While we were perfectly capable of building bridges before Newton formalized the laws of motion and gravity, his work allowed us not only to understand the forces involved in physics but also to leverage this knowledge to construct skyscrapers and launch rockets. Similarly, by applying computational methods and systematic analysis to biological systems, techbio might offer us the tools to predict, model, and eventually manipulate biological systems with unprecedented precision, potentially leading to transformative advancements in medicine, biotechnology, and our overall comprehension of living systems.

‍

FROM YOUR PERSPECTIVE, WHAT RECENT INNOVATION HAS HAD THE GREATEST IMPACT IN TECH/HEALTH?

From a healthcare perspective in developed nations, the rapid development of mRNA-based COVID-19 vaccines stands out as a recent innovative breakthrough. This technology allowed for an unprecedented swift response to the pandemic, significantly reducing potential death tolls and economic damage by preventing the collapse of healthcare systems.However, I find the logistical innovations and persistent efforts in global disease eradication even more impressive. The successful eradication of smallpox, the near-elimination of polio, and the promising progress against malaria showcase humanity's ability to combat devastating diseases on a global scale. The impact of these achievements in terms of lives saved and suffering prevented is immeasurable and represents a monumental stride in public health.

‍

Originally from California, Gavin received his BA at the University of California, Berkeley, and completed his Internal Medicine Residency at Stanford. This year, he began his Hematology & Oncology Fellowship at UCLA. He is interested in the intersection of big data and cancer care. Outside of his professional career, he enjoys watching the Lakers and playing basketball.

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

AI integration in healthcare delivery

‍

GREATEST ACCOMPLISHMENT

Staying close to family and friends through medical training

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD GREATEST IMPACT ON TECH/HEALTH

DNA/RNA sequencing and the advancements of cancer therapeutics from cytotoxic chemotherapy to more precise and targeted treatments

"Grant is a current 4th year PhD candidate in Bioinformatics at UCSF. As a member of the Vasilis Ntranos Lab at the UCSF Diabetes Center, he is interested in applying techniques from natural language processing to interpret protein-coding variation. His past work has demonstrated that protein language models are accurate and scalable predictors of mutation pathogenicity, and that different classes of mutations (i.e., substitutions versus deletions) can systematically differ in their effects, mediated by structural and sequence contexts.

Before UCSF, Grant spent two years as a research assistant developing techniques in population and statistical genetics, which inspired him to pursue a career in Bioinformatics. He holds undergraduate degrees in Applied Math and Economics from Brown University.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

Approximately 90% of drug candidates fail clinical trials, increasing costs and reducing patient access. However, drug candidates supported by human genetic evidence are far more likely to succeed in trials, suggesting that genetics can play a crucial role in supporting new therapeutics. While genetics has already successfully informed therapeutic development for specific indications, I am excited for a future where genetics is readily integrated into all parts of the drug discovery and development process.

‍

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

I’m a huge reality TV fan, and Emily Nussbaum’s ""Cue the Sun"" was a fascinating look into the history of the genre and its impacts on culture, politics, and the broader entertainment industry.

‍

FROM YOUR PERSPECTIVE, WHAT RECENT INNOVATION HAS HAD THE GREATEST IMPACT IN TECH/HEALTH?

AI models are highly data-intensive, and AI advances in biology were only made possible by training on massive amounts of publicly available, harmonized data. Thus, efforts to curate and aggregate vast amounts of biological data (and make this data publicly accessible) have an outsized impact on biotech and healthcare.

Gunnar is a fourth-year MD student at UCSF with a robust research background and industry experience. His work ranges from regenerative medicine to digital health and he brings valuable insights from the private sector. Gunnar graduated from Johns Hopkins University with a BS in Biomedical Engineering, concentrating on the translational research of tissue engineering and the clinical applications of biomaterials. After completing his undergraduate studies, he worked with Johnson & Johnson's Global Public Health group across therapeutic initiatives of HIV, Tuberculosis, Ebola, COVID-19, and mental health, striving to make life-saving innovations available, affordable, and accessible for the world’s most underserved populations. He also earned an MPH from Johns Hopkins Bloomberg School of Public Health, focusing on the health security implications of biotechnology, including dual-use oversight of research related to gene editing and synthetic biology. Beyond his academic pursuits, Gunnar is deeply committed to environmental and climate advocacy within his community.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

The development of lab-grown organs and tissues that are tailored to a patient’s specific needs, thereby minimizing the risks of organ transplantation, reducing the demand for organ donors, and solidifying regenerative medicine as a cornerstone of modern medicine and personalized healthcare.

‍

WHAT EXCITES YOU MOST ABOUT TECHBIO?

The opportunity for innovations in technology to influence the future of medicine and transform the way that we personalize care for our patients. It is inspiring to see ventures that are not only pushing the boundaries of innovation but also taking the initiative to translate their ingenuity into groundbreaking products with the potential to dramatically improve health outcomes on a global scale.

‍

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

The Will of The Many by James Islington – it is an enthralling story that explores themes of power, resilience, and systemic inequity to comment on access and control of knowledge within society.

Guy is a neuroscience PhD student at Stanford University, where he works with Professor Krishna Shenoy of the Stanford Neural Prosthetics Translational Laboratory (NPTL) and Professor Shaul Druckmann in the Department of Neurobiology. He previously studied mathematics and molecular biology at the University of California, Berkeley, where he worked in Professor Robert Knight's lab analyzing EEG and ECoG recordings.

Guy joined the BrainGate clinical trial team in 2019, where he works on algorithms for intracortical brain-computer interfaces (BCIs). His research focuses on translating basic science into high-performance BCI systems, leveraging unparalleled access to high spatiotemporal resolution signals from individual brain cells. This includes prototyping speech decoding systems, as well as building robust systems that can fare against changing neural signals, with the ultimate aim of helping move BCIs from the lab and into the clinic.

While born on the east coast, Guy has traded teams and embraced the mild California climate. He enjoys hiking around the Bay Area in his spare time.

‍

MOST INFLUENTIAL CONTENT READ/LISTENED TO IN PAST YEAR

"War and Peace and War" by Peter Turchin

‍

WHAT EXCITES YOU ABOUT ARTIS

Being part of a team that's helping expand the TechBio frontier alongside some really interesting companies. Tons of fascinating science as well as healthcare advances.

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD GREATEST IMPACT ON TECH/HEALTH

I would love to mention a cool neuroscience discovery here but it would have to be CRISPR. Precise sequence targeting has massively aided basic biology research and will likely provide groundbreaking therapies in the coming years.

Isaac is a fourth-year PhD student at the University of Cambridge in Psychiatry and Computer Science. A Gates-Cambridge scholar, his research combines large-scale data in neuroimaging and genetics to understand the network structure of the human brain and how it relates to mental illness. More generally, Isaac is interested in approaching open questions in biology – from genomics to imaging and beyond – by creating new, bespoke computational methods that leverage biological knowledge, rather than relying on existing off-the-shelf techniques. Isaac is also passionate about science communication, and enjoys writing for popular news outlets as much as for peer-reviewed journals. Before his PhD, Isaac studied molecular biology at Harvard University (A.B.) and computer science and machine learning at Cambridge (MPhil). If he’s not at his computer, you can probably find Isaac making music, out on a run, or baking a cake.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

I hope to see a wave of novel, effective therapies for neuropsychiatric disorders. I believe we are on the precipice of a sea change in how we treat mental illness; the scope and scale of emergent technologies – including brain stimulation, psychedelic therapy, neuroimmune drug development, and AI-guided precision treatment – leave me excited that a radical shift may be just on the horizon.

WHAT EXCITES YOU MOST ABOUT TECHBIO?

For me, the promise of TechBio boils down to two words: creativity and impact. I have yet to come across another space so intent on combining such creative, interdisciplinary innovation with a clear vision for global (human) impact.

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

"Walk Through Walls" by Marina Abramovic. Reading this autobiography, I felt so privileged to be let into the unique mind of someone who has fundamentally redefined our conception of “art,” while maintaining such clarity of vision, purpose, and meaning.

Jeremiah Sims is an MD-PhD student at the University of Washington, where he studies under the mentorship of David Baker in the Institute for Protein Design. His ongoing work focuses on data-driven deep learning approaches to improve protein interface design and function, towards the goal of de novo protein therapeutics for infectious diseases. Jeremiah’s research focus anticipates a career in the protein-based pharmaceutical space, one that he hopes will be aided by recent technological advances in the laboratory and the clinic.

Hailing from Richmond, VA, Jeremiah developed deep passions for science, medicine, soccer, and music. As an undergrad, he studied Chemistry and began protein drug research in Elsa Yan’s Lab before pursuing a postbaccalaureate position at the NIH, where he developed an assay to probe malaria nutrient uptake.

In addition to being an ARTIS Fellow, Jeremiah is honored as this year’s Jim Valentine Fellow in homage of a great friend and longtime mentor of ARTIS who passed away after his long courageous fight with cancer. Jim is remembered for his brilliance, larger-than-life personality, and razor-sharp wit. He believed in taking risks, grand visions, and an entrepreneurial spirit, all the while maintaining his sense of humor. As a Valentine Fellow, Jeremiah embodies the technical expertise to drive innovation forward and the clinical focus to translate this research to impact human lives.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

I hope to see an increased emphasis on personalized medicine, especially in a way that can appropriately balance the ways that we as humans are similar and different. I am optimistic that new machine learning tools to design novel therapeutics will facilitate the development of treatment plans that are right for each patient.

‍

GREATEST ACCOMPLISHMENT

Despite rarely overlapping and demanding career schedules, my friend and I managed to complete and release an album that gained some mainstream support. It was an incredible experience to channel our creativity together, and our small success has reinforced to me the importance and joy of relentlessly pursuing creativity within and outside our careers.

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

The Color of Law, by Richard Rothstein, was a great introduction into the roles that different levels of U.S. government played in the socioeconomic subjugation of Black Americans. Entertaining and pithy, it is a well-resourced book that hints at the multifaceted impact that location, food, environment, and social resources play in determining generational outcomes.

Jessika is a second year MD/PhD candidate at Harvard Medical School with a broad range of research expertise, having worked previously at UC Berkeley and Stanford Medicine. She is primarily interested in computational biology, oncology, and immunology, and runs the Oncology Interest Group at Harvard Medical School.

She obtained her Bachelor’s degree in Biology, focused on Computational Biology and Genomics, and minored in Computer Science and Mathematics at Washington University in St. Louis, where she was awarded the Florence Moog Fellowship and was a part of the University Scholars Program. There, she worked with Dr. Li Ding, and focused primarily on cancer multi-omics research and better characterizing protein complexes integral to cancer progression. For her research, she has been named a Barry Goldwater Scholar and an Astronaut Scholar, and received the 2019 Palantir Women in Technology Scholarship.

She grew up in the Bay Area in California and enjoys spending free time in nature, choreographing and teaching dance, and trying new cuisines to fuel her inner foodie.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Successful preventative treatment approaches to chronic pain

‍

WHAT EXCITES YOU ABOUT ARTIS

I can't wait to work alongside the other fellows and the AV community in creating tangible, lasting change.

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD GREATEST IMPACT ON TECH/HEALTH

AlphaFold 2

Julian Horwitz is a transplant surgery fellow at UCLA. He grew up in a small town outside of Boston.

Julian received his MD from the NYU School of Medicine and completed a general surgery residency at the Mount Sinai Hospital in NYC. During residency, Julian spent two years as a post-doctoral research fellow in a translational transplant immunology lab at the Icahn School of Medicine at Mount Sinai, focusing on novel approaches to achieving immune tolerance.

Julian is an avid skier and he loves spending time with his wife and dog, Peanut.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

The foremost problem in the field of transplantation is the massive discrepancy between the number of patients on organ waiting lists (demand) versus the supply of organs for transplantation from deceased and living donors. I hope to see the transplant community overcome the supply issue through advances in the fields of xenotransplantation and bioengineered organs.

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

'10% Happier' by Dan Harris. A pragmatic and entertaining introduction to mindfulness and meditation. Within clinical medicine, mindfulness and wellness initiatives are being increasingly emphasized to address rising levels of physician burnout.

‍

GREATEST ACCOMPLISHMENT

Being awarded the Arthur H. Aufses Jr., MD Prize in Surgery award (named after the prior Mount Sinai surgery chair) at my residency graduation for clinical excellence and leadership.

Kamal is an MD-PhD candidate at Stanford in the Kundaje and Daniels labs. Prior to returning to Stanford, Kamal was founder of Nebula Genomics and had a short stint at Google and then as a Gates-Cambridge scholar at the University of Cambridge. He went to Harvard for undergrad.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

More precise and effective interventions for addressing mental health. The past few years have seen a lot of novel approaches and I hope we continue to see progress

‍

WHAT EXCITES YOU MOST ABOUT TECHBIO?

The opportunity to cross the chasm and take advantage of rapid advancements in technology and use them to improve healthcare.

‍

‍

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

The Tartar Steppe by Dino Buzzati is a great non-fiction book that provides a compelling argument for why we should find meaning in the little things

‍

FROM YOUR PERSPECTIVE, WHAT RECENT INNOVATION HAS HAD THE GREATEST IMPACT IN TECH/HEALTH?

I think it's hard to argue against AI. We are finding applications for AI in everything from designing proteins to building digital health coaches.

‍

WHAT IS YOUR GREATEST ACCOMPLISHMENT?

Starting Nebula Genomics and helping people (many rare disease patients) in over 100 countries get access to affordable next-generation DNA sequencing.

Luke is a PhD candidate at the University of Oxford, where he works at the intersection of neuroscience and psychology. In his research, Luke combines cutting-edge brain imaging, brain stimulation, and quantitative modelling techniques to understand how brain activity gives rise to fundamental aspects of cognition and behaviour. Before studying at Oxford, Luke completed a B.A. in Philosophy and Psychology at the University of Sydney. Outside of work, he enjoys spending time on the tennis court, playing and listening to music, and contemporary art.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

I hope to see individualised phenotyping and treatment become standard in all fields of medicine. I think that this will be particularly important for psychiatric and neurological disorders, where patients with the same diagnosis often exhibit strikingly divergent symptom patterns.

‍

WHAT EXCITES YOU MOST ABOUT TECHBIO?

Everything! But in particular, I'm excited about novel computational techniques that can capture and predict biological processes 'in silico'. Better models of biological phenomena will facilitate the design of more effective experiments, provide deeper insights from the data we have, and ultimately drive the development of superior medical therapies at faster rates than ever before.

‍

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

“Why Trust Science?”, by scientist-turned-historian, Naomi Oreskes. It is a timely and erudite history of science as a form of human activity: how it works, why it works, and the social and political responsibilities of scientific practitioners to ensure that public trust is not broken.

Madelynn is an NSF Graduate Research fellow pursuing a PhD in Bioengineering at the University of Pennsylvania. Her primary research focuses on engineering novel gene editing approaches to reduce cardiovascular disease risk and reverse metabolic disease-causing mutations. She aspires to pioneer the development of gene editing therapies, hoping to translate them as the next form of personalized medicine.

‍

As a California native, Madelynn earned her Bachelor of Science degree in Bioengineering from UC Berkeley, with a primary research focus on cardiovascular science at the Gladstone Institute of UCSF. After graduation, she pursued a post-baccalaureate research position at Massachusetts General Hospital, where she specialized in characterizing novel engineered CRISPR-Cas9 variant proteins.

‍

When she's not in the lab, you'll find Madelynn on the beach volleyball court, rollerblading along the Philadelphia Schuylkill River trail, or enjoying a sitcom episode (or two).

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

I hope to witness two major advancements:

1 - The development and translation of personalized medicine for Mendelian genetic disorders, allowing for immediate treatment after birth or, in cases where symptoms manifest during fetal development, in utero intervention.

2 – Complete understanding of Alzheimer's Disease (AD) through accurate mechanistic insights, the development of reliable AD biomarkers usable in routine primary care appointments, and the creation of effective treatments or cures applicable in the disease’s early stages.

‍

GREATEST ACCOMPLISHMENT

Earning authorship on a paper published in Science right after college was a monumental effort and a notable achievement on paper. In a non-traditional sense: creating a music video to recruit grad students for my previous lab, set to the tune of "The Fresh Prince of Bel-Air"

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

This past spring, Julia Vitarello delivered a powerful and intimate talk to a select audience of leading gene editors and their students. She is a remarkable mother who, despite not having formal scientific training, single-handedly developed an ASO therapy for her daughter who died from Batten Disease in 2021.

Julia navigated the complexities of the FDA to obtain special approval for her precision drug tailored to her daughter’s disease-causing mutation. Julia’s talk emphasized that every patient, regardless of the rarity of their mutation, deserves efforts towards finding a therapeutic solution.

Morgan is a fourth year PhD candidate and NSF graduate research fellow in the interdisciplinary Health Sciences and Technology (HST) program at Harvard and MIT. As a member of the Mitragotri Lab at Harvard SEAS, her interests span the fields of drug delivery and cell therapy with ultimate applications in immuno-oncology. Her research focuses on (i) the development of drug delivery technologies to locally manipulate cell therapies and (ii) the use of bioinspired materials to tune the kinetics of cancer vaccines.

Outside of the lab, she is passionate about engaging with the biotech community in Cambridge to create forums for discussion and innovation. She serves as co-president of the MIT Biotech Group and is a co-founder and leader of the Area Two Bio Fund, an investment club for publicly traded biotech companies.

Morgan received her BS in Bioengineering from the University of Maryland. In her free time, she enjoys doing gymnastics, hiking, pageantry, and finding the best matcha lattes in Boston.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

"One and done" therapies for chronic, multifactorial diseases like heart disease

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

Various non-fiction books and articles about gerotherapeutics - drugs with the potential to extend healthspan and lifespan by mitigating age-related disease

‍

RECENT INNOVATION OR DISCOVERY

Base and prime editing, which have greatly expanded the space of genetic diseases potentially addressable using CRISPR

Nezar is a Postdoctoral Researcher at MIT, where he also did his PhD in computational biology, specializing in the 3D organization of the genome and its relationship to the epigenome. He is from Ottawa, Canada and now lives in the Boston area.

His life sciences studies began in biochemistry and biophysics, and now are heavily focused on data science, machine learning and scientific software development initiatives to drive biomedical discovery.

Nezar also loves working across disciplines, exploring connections between disparate fields such as genomics and quantitative finance.

Outside of science, software, and entrepreneurship, he enjoys running, sketching and playing with his infant daughter.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Better public health monitoring integrated into our urban infrastructure. As modern societies we will need to develop a better collective immune system to intercept and curtail emerging infectious diseases before they become pandemics.

‍

GREATEST IMPACT IN TECH/HEALTH

Next-generation DNA sequencing. As Linus Torvalds once said about Git “If you can do something really fast really well people start using it differently”. I’d add “really cheap” to that list. Low cost NGS allowed us to not just use sequencing for its own sake (assemble genomes and call variants), but gave rise to all the “Layer 2” technologies that exploit DNA sequencing as a readout to profile and measure all kinds of other biological information that has and will continue to revolutionize medicine.

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

I recently read Ray Dalio’s book on managing debt crises, which has changed my perspective on the dynamics of credit (and stimulus) in economic cycles.

Niraj Mehta is a Partner at ARTIS Ventures.

Niraj is focused on on sourcing, diligencing, and supporting companies in the therapeutics space.

Niraj currently holds 5 board seats across the ARTIS portfolios. Previously an ARTIS Fellow, he holds a PhD from Stanford University in Chemistry, where, under the mentorship of Dr. Elizabeth Sattely, he contributed to multiple scientific publications in top-tier journals, including a first-author publication in Cell. Niraj has vast experience in therapeutic drug development and genetic drug markets; before joining ARTIS, he led business development eMorts at Emcure Pharmaceuticals, a large multinational generic drug company. Niraj completed his undergraduate studies with a BS in Chemical Engineering from UCLA.

‍

Investments & Boards

OverT, Delix, and Pi Bio

‍

Niru is a second year cardiology fellow at Boston Medical Center/Boston University. She earned her MD and graduated cum laude from Boston University School of Medicine. She completed her residency in Internal Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School and later worked as an attending physician there in the division of Hospital Medicine. She also worked as a clinical scientist at Anumana, Inc., where she focused on study design and validation of AI-ECG algorithms for early diagnosis of cardiovascular disease. Her clinical research concentrated on disparities in outcomes amongst underrepresented populations with advanced heart failure requiring left ventricular assist devices (LVADs). She has an interest in medical device development and plans to pursue an additional fellowship in interventional cardiology. She is excited to bring her blend of clinical expertise and interest in technological innovation to ARTIS.

‍

WHAT IS A HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME?

Advancements in personalized medicine, particularly through the use of AI and big data. The analysis of large data sets can provide precise insights to tailor treatments to individual genetic, environmental, and demographic factors. Hopefully this will lead to more effective therapies that can benefit populations that were previously underrepresented in clinical trials.

‍

WHAT IS THE MOST INFLUENTIAL CONTENT YOU READ LAST YEAR?

Outlive: The Science and Art of Longevity by Peter Attia

‍

WHAT IS YOUR GREATEST ACCOMPLISHMENT?

Persevering through my first year of internal medicine residency during the height of the COVID pandemic in March 2020.

Omair Khan is a Partner at ARTIS Ventures.

Omair is focused on sourcing, diligencing, and supporting companies in the therapeutics and healthcare technologies sectors. Omair currently holds 5 board seats across the ARTIS portfolios.

Previously an ARTIS Fellow, Omair is pursuing his MD-PhD dual degree at Stanford University with a focus on stem cell biology and regenerative medicine under the mentorship of world-renowned immunologist and stem cell biologist, Dr. Irving Weissman. Omair was recently selected as a recipient of the Paul and Daisy Soros Fellowship for New Americans, a fellowship for individuals with sustained accomplishments who are poised to make significant contributions to their fields of study and the United States at large. Before joining ARTIS, Omair had diverse experiences spanning clinical medicine, industry, global health, and government. Omair completed his undergraduate studies with a BS in Molecular, Cellular, and Developmental Biology and Global Health Studies from Yale University where he was awarded the Edgar J. Poell Prize for most outstanding thesis.

‍

Investments & Boards

Onto Health, All in Bio, OverT, and Slope

‍

Incubated

Onto Health

Patrick is in the sixth year of his PhD at the Johns Hopkins School of Medicine. As a member of David Linden’s lab, he focuses on understanding the mechanisms underlying neuroplasticity and their translational applications across a broad spectrum of pathologies from injury and degeneration to mood and neuropsychiatric disorders. His current research seeks to understand and characterize the regenerative potential of the adult mammalian brain.

Patrick is an avid member of the Hopkins and greater Baltimore community. He served as the President of Pro-Bono consulting for the Johns Hopkins Graduate Consulting Club where he sourced client companies and connected them with diverse teams of graduate students to solve business strategy related problems. He also co-founded a charitable non-profit, the Baltimore Electronic Collective, with a mission of providing a platform for and promoting local music artists. Outside of work he enjoys hiking, cooking, and mixing music.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

I would love to see technical and systematic advancements in the detection, diagnosis, and treatment of neuropsychiatric and mood disorders.

‍

GREATEST IMPACT IN TECH/HEALTH

Open-source version control systems such as Git.

Continued advancements in computational resources that enable critical scientific techniques from NGS and expression profiling to neuroinformatics.

MOST INFLUENTIAL CONTENT READ LAST YEAR

Mustards by Cindy Pawlcyn and The Wok by Kenji Lopez-Alt. Two cookbooks that have re-inspired my sense of creativity in the kitchen.

Quang is an Oxford-Hoffmann DPhil Candidate at the University of Oxford in the Nuffield Department of Medicine. His research integrates high-parameter experimental and computational analyses to identify novel CD8 T cells with immune regulatory functions in human lymphoid tissues. Quang co-founded the Science & Innovation Club at Oxford with faculty advisorship from the Saïd Business School. The club aims to bring research graduates from diverse disciplines in conversations with industry and investors about how to think and do science beyond the laboratory.

Quang moved from Vietnam to the US as a teen. He obtained his BS in Cell and Molecular Biology from Duke University. There he explored how gut microbiota influence B cell and antibody responses against HIV/SIV in the lab of Dr. Sallie Permar at the Duke Human Vaccine Institute. After college, Quang received a scholarship from the US NIH to work on HIV latency and cure in the lab of Dr. Richard Koup and Dr. Joseph Casazza at the Vaccine Research Center. He pursued an Erasmus LIVE MSc program in Vaccinology, rotating through Spain, Belgium and France. He conducted his master's thesis at GSK Vaccines where he proposed a study examining immunosenescence and vaccine responses in older adults. During this time, he also worked remotely as a research manager for an international public health network in the team of Prof. Bach Tran based in Hanoi, Vietnam.

In his free time, Quang enjoys learning mobile phone app development, reading, taking walks, volunteering in various college and scholarship committees, and having philosophical conversations.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

A vaccine given to young people to prevent neurodegenerative diseases in older adults.

‍

MOST INFLUENTIAL CONTENT LAST YEAR

'Hiểu Về Trái Tim' ('Understanding the Heart') is a book written by a well-respected Vietnamese monk about how to take control of our mind in time of challenges and opportunities.

‍

GREATEST ACCOMPLISHMENT

Despite money being an issue in my family, I have managed to fund meaningful activities I have wanted to pursue. All my education up to now has been fully paid by various organizations, including the Bill & Melinda Gates Foundation, Michael & Susan Dell Foundation, Greenhouse Scholars, NIH, & National Association for the Education of Homeless Children and Youth.

Reuben is currently enrolled in a Medical Scientist Training Program (MD/PhD) at University of California, San Francisco and starting his graduate training in the Krogan Lab, where he will be investigating the protein-protein interactions of APOE4 that account for its correlation with Alzheimer's disease.

His focus is on fostering the next generation of cellular and gene therapies that will address longstanding unmet needs for patients with chronic illness.

He obtained his Bachelor's in Molecular Biology & Biochemistry at Washington University in Saint Louis. Reuben has a broad range of research experience as a former Amgen Scholar at UC Berkeley and a MARC-uSTAR student at WashU among other research titles.

Proudly born and raised just outside New Orleans, LA, Reuben enjoys his free time making and eating good food and catching live music whenever possible. He balances this with time spent in the gym or hiking to offset his complicated relationship with butter and bacon. As a Black man, Reuben takes seriously his opportunities to champion STEM-related careers and their applications to young underrepresented minority students and can always be found in Black community organizations at UCSF.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

With the arrival of gene-editing technologies, we are looking at a world where we can develop treatments that are more sustainable for patients by solving diseases rather than creating dependencies on medication. My family has always struggled with high levels of "bad" cholesterol, or LDL. Most of them were prescribed statins. With treatments such as those that edit the PCSK9 gene, families like mine may one day have an enduring alternative to the medications they pay for and take daily.

‍

GREATEST IMPACT IN TECH/HEALTH

With CRISPR we can determine the function of almost any gene by generating knockouts in different settings. We can even use CRISPR variants to understand the consequences of increasing or decreasing expression of a gene in a cell at any time in any condition. This has huge potential for identifying genes that are important in different diseases. While CRISPR may or may not make big splashes in the clinic, it has already made big splashes in research that will accelerate our understanding of many different diseases.

‍

GREATEST ACCOMPLISHMENT

Completing my MD/PhD application cycle with offers from nine universities. I did a gap year in the Bay Area working as a lab technician in the McManus Lab at UCSF and during that time I was also going through the application process. I was commuting an hour and a half to lab, working, taking classes and teaching at night. It was the busiest I had ever been. But after it all, I ended my cycle with nine admissions, and my choice of where to go. I really never thought I would pull it off and to that degree.

Rishub is a fourth year MD candidate at Vanderbilt University and comes to ARTIS Ventures with extensive research and prior investment experience. He is interested in surgical innovation, medical devices, aesthetic and wellness medicine, solid tumor biology and treatment, and improving health equity. He is a finance and Dermatology director of the Shade Tree Clinic, a student-run free clinic for the uninsured, and is president of the Social Mission Committee at Vanderbilt.

‍

WHAT EXCITES YOU ABOUT ARTIS

ARTIS' approach to disruption and targeting the TechBio space is authentic and scientifically-guided. The Fellows program is a testament to the value ARTIS places on scientific and clinical diligence - it's truly unique!

GREATEST IMPACT IN TECH/HEALTH

ChatGPT has had a tremendous impact on both technology and health - for surgeons, this tool can be helpful to summarize post-operative instructions or create plain language summaries of complex medical conditions and treatments.

MOST INFLUENTIAL CONTENT READ LAST YEAR

A briefing on the Center for Medicare and Medicaid Services' reversal of their proposed policy to adjust billing codes for breast reconstruction that would limit access and exacerbate health disparities - it was inspiring to read how much patient and surgeon advocacy matters and can have an impact!

‍

Sneha is a chief fellow in cardiovascular medicine at Stanford University. Her entrepreneurial and research interests focus on the development and clinical trials of AI in healthcare, with a particular passion for initiatives focused on cardiovascular risk reduction.  

Sneha received her BS in Economics from Duke University, MD from the Johns Hopkins School of Medicine, and MBA from Harvard Business School. During her time at Harvard Business School, she worked at Moderna Therapeutics and the VC firm Flare Capital. Prior to fellowship, she was an internal medicine resident at Columbia/NewYork-Presbyterian, during which time she was selected as a Silverman Fellow in Healthcare Innovation. In this capacity, she worked with clinical and data science partners to build and deploy the technological infrastructure to identify patients with certain cardiac conditions earlier in the course of their disease. She currently works with the Stanford Center of Clinical Research and the Data Science team. Her work focuses on AI evaluation and implementation into clinical workflow at Stanford. Outside of work, Sneha enjoys hiking, traveling, reading, trying new restaurants, and finding the best cappuccinos in the Bay Area. 

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

A shift to prevention and personalized medicine as the core of healthcare.

‍

WHAT EXCITES YOU ABOUT ARTIS

The incredible team and the opportunity to blend my clinical, innovation, and academic interests in the TechBio space.

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

The book “The Artist’s Way”, specially for the daily practice of morning pages.

‍

Stella is a doctoral researcher at Charité Berlin, where she investigates optimal design of vaccination centers drawing on machine learning techniques and policymaker insights.

Stella has always been passionate about healthcare innovation in underserved areas. Accordingly, she has built an interdisciplinary profile combining private and public sector experience at local, national and international level in healthcare. She studied health economics, politics, and history at Sciences Po Paris, London School of Economics, and London School of Hygiene and Tropical Medicine.

Following her studies, she worked as a project manager and consultant with a focus on market access and business strategy at the OECD, the Red Cross, the German Federal Ministry of Health and McKinsey & Co. 

At McKinsey, Stella advised clients across pharma, medtech and global public health. When the COVID-19 pandemic broke out, she joined the German Ministry of Health’s COVID response unit, coordinating the development of national testing and vaccination strategies.

Stella augmented her strategic skillset with more hands-on experience in product design and innovation as a Biodesign Innovation Fellow at Stanford University in emergency medicine and as mentor for social innovation and healthcare start-ups, with a focus on women's health projects.

Stella is currently based in Europe. In her free time, she enjoys hiking, surfing, board games, and DIY projects.

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

Re-read Daniel Kehlmann’s “Measuring the World”. The novel juxtaposes two ways of exploring planet earth and how it works: on one side geographer Humboldt’s empirical exploration hiking mountains, measuring trees, collecting specimen. On the other side, mathematician Gauss’ theoretical exploration through equations.

‍

WHAT EXCITES YOU ABOUT ARTIS

The bold multifaceted vision of future healthcare, investment with a platform lens, and a fantastic team!

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Healthcare services and financing mechanisms that allow for equitable access to novel therapies independent of individual wealth, location and origin.

Tom is currently a DPhil student at the University of Oxford. As part of his PhD, he is using longitudinal single cell RNA sequencing (scRNA seq) to decipher the cellular determinants of anti-TNF therapy response across inflammatory bowel disease and rheumatoid arthritis.

Tom graduated from the University of East Anglia (Norwich, United Kingdom) and did his internship at the Queen Elizabeth Hospital in Birmingham. He is currently a practising physician at the John Radcliffe Hospital in Oxford.

Tom has published over 30 research papers in medicine, across gastroenterology, rheumatology and mental health. He has peer-reviewed for Gut, Clinical Gastroenterology and Hepatology, Annals of the Rheumatic Diseases and Rheumatology. As part of his role as the Arthritis Therapy Acceleration Program (ATAP) Fellow at the Kennedy Institute of Rheumatology, he has collaborated with multiple biotech and pharmaceutical companies on early research and development as well as clinical trial design. Tom has previously interned at GE Healthcare Finnamore (now GE Healthcare Partners), a management consulting firm.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Moving from a standardised 'one size fits all' approach in the treatment of immune-mediated inflammatory diseases to a more targeted treatment approach, driven by examination of molecular pathotypes of inflammation in individual patients.

‍

GREATEST IMPACT IN TECH/HEALTH

scRNA sequencing, in conjunction with a deeper understanding of the tissue microenvironment courtesy of spatial transcriptomics and in time, high throughput single cell proteomics, will change modern medicine across the coming decades. Combining the transcriptomic profile of cells with high throughput single cell proteomics will hopefully not only enable deeper understanding of biology but also enable a lower failure rate in drug development.

‍

GREATEST ACCOMPLISHMENT

Graduating from medical school at 21 years old.

Tommaso is a Postdoctoral Scholar at the University of California, San Diego. He received his training in multiple engineering disciplines, with a particular emphasis on neural engineering and robotics. He completed his B.Sc. at the University of Padova, Italy, M.Sc. at the University of Pisa, Italy, and PhD at the University of California, Riverside.

Tommaso's current research interests lie in the emerging intersection of neuroscience, machine learning, and control engineering. He studies biologically inspired recurrent neural networks. Previously, he focused his PhD thesis on reverse engineering brain-wide neural synchronization phenomena to inform novel neurostimulation and neural therapeutics methods. During his graduate studies, he also interned at the Advanced Telecommunications Research Institute International (ATR) in Japan, where he developed data-driven models for neurofeedback therapies.

Outside of work, Tommaso loves spending time outdoors. Besides being an avid hiker and backpacker, he enjoys surfing, golfing, and skiing.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

Unraveling the structure-function relationship in the human brain may become possible in a not-so-distant future thanks to relentless advances in probing technologies. Understanding the mapping between the brain’s anatomical organization and its complex dynamics will inform the development of novel, system-wide interventions for neurological and psychiatric disorders.

‍

GREATEST ACCOMPLISHMENT

Successfully advocating for the creation of a Covid Relief Fund for international students affected by financial hardships.​

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

"The man who mistook his wife for a hat and other clinical tales” by the neurologist O. Sacks. It contains a collection of the most unique case histories of the author’s patients. Besides many touching stories, the book provides insightful examples of how the advent of modern brain probing techniques allowed scientists to shed a light on the most unusual outcomes of neurological damage.

Will is completing his PhD at Northwestern University in the labs of Dr. Josh Leonard and Dr. Gabe Rocklin, researching at the interface of mammalian synthetic biology and protein design to engineer new synthetic receptors and further our understanding of how they function. Prior to Northwestern, he worked at Amyris, a synthetic biology company aiming to produce renewable products through metabolic engineering, and before that he received his undergraduate degree in Biology from Carleton College. Outside of work, Will enjoys spending as much time as possible outside by playing soccer, biking around Chicago, and canoeing and fishing his way through northern Minnesota.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

I would love to see rare genetic disorders become more treatable. We’re still in the early stages of creating effective gene therapies, which is gaining greater clinical success year after year.

‍

GREATEST ACCOMPLISHMENT

Once catching an adult snapping turtle from a lake with my bare hands.

‍

GREATEST IMPACT IN TECH/HEALTH

We’re still in the early stages but beginning to see the fields of computational and de novo protein design take off. With the recent advancements in structural prediction from sequence alone, and design from protein language and diffusion models, I think that the protein engineering community is poised to make some incredible advancements for therapeutics and biotechnology within the next decade.